Anti-Inflammatory Biologics Market Developments And Opportunities Across 2026–2030

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Anti-Inflammatory Biologics Market In 2026, And How Will Its Value Evolve By 2030?

The anti-inflammatory biologics market size has shown robust growth in recent years. It is anticipated to expand from $118.02 billion in 2025 to $128.84 billion in 2026, at a compound annual growth rate (CAGR) of 9.2%. This historical growth can be attributed to factors such as the limited availability of biologics, reliance on traditional anti-inflammatory drugs, the increasing prevalence of rheumatoid arthritis and psoriasis, the development of hospital and clinic infrastructure, and rising investment in immunology research.

The anti-inflammatory biologics market is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach $180.93 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.9%. Several factors are contributing to this projected growth, including the advancement of next-generation cytokine inhibitors, the broadening availability of home care and self-administration methods, a rise in regulatory approvals alongside accelerated clinical trial procedures, increased funding directed towards precision medicine and biologics research and development, and the burgeoning collaborations between pharmaceutical and biotechnology firms. Key trends anticipated during this period encompass the increasing acceptance of targeted biologics for long-term inflammatory conditions, the broader application of subcutaneous and injectable drug delivery systems, a surge in clinical trials and investigations into new anti-inflammatory biologics, a greater emphasis on customized treatment strategies, and enhanced awareness and availability of biologics in emerging markets.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25695&type=smp

Which Factors Are Influencing The Growth Of The Anti-Inflammatory Biologics Market?

The increasing incidence of arthritis is projected to drive the expansion of the anti-inflammatory biologics market in the future. Arthritis is characterized by the inflammation or swelling of one or more joints, leading to discomfort, rigidity, and impaired mobility, frequently deteriorating as individuals age. This growing occurrence of arthritis largely stems from escalating obesity rates, given that surplus body weight exerts extra pressure on joints, contributing to inflammation and joint breakdown. For individuals suffering from moderate to severe arthritis, anti-inflammatory biologics prove beneficial by targeting particular elements of the immune system, thereby lessening inflammation, decelerating joint deterioration, alleviating symptoms, and enhancing physical capabilities and overall well-being. As an illustration, in January 2024, data from the Office for Health Improvement and Disparities, a UK government department, indicated that in 2023, 18.4% of individuals aged 16 and above reported experiencing a long-term MSK condition, which was an increase from 17.6% recorded in 2022. Consequently, the expanding occurrence of arthritis is stimulating the development of the anti-inflammatory biologics market.

How Is The Anti-Inflammatory Biologics Market Categorized Across Its Segment Groups?

The anti-inflammatory biologics market covered in this report is segmented –

1) By Drug Class: Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, B-Cell Inhibitors, T-Cell Inhibitors, Other Drug Classes

2) By Route Of Administration: Oral, Injection, Intravenous, Subcutaneous

3) By Application: Rheumatoid Arthritis, Inflammatory Bowel Disease, Psoriasis, Other Applications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

5) By End-Users: Hospital, Clinics, Home Care Settings, Research And Academic Institutes

Subsegments:

1) By Tumor Necrosis Factor Inhibitors: Adalimumab, Infliximab, Etanercept, Golimumab, Certolizumab Pegol

2) By Interleukin Inhibitors: Interleukin-1 Inhibitors, Interleukin-6 Inhibitors, Interleukin -12 Or 23 Inhibitors, Interleukin -17 Inhibitors, Interleukin -23 Inhibitors

3) By B-Cell Inhibitors: Rituximab, Ocrelizumab, Ofatumumab

4) By T-Cell Inhibitors: Abatacept, Alefacept

5) By Other Drug Classes: Janus Kinase Inhibitors, Anti-IgE And Other Biologics

Which Trends Are Shaping The Anti-Inflammatory Biologics Market?

Major companies in the anti-inflammatory biologics market are concentrating on developing innovative solutions, such as interleukin-6 (IL-6) receptor antagonists, to target chronic inflammatory diseases with increased specificity and fewer side effects. Interleukin-6 (IL-6) receptor antagonists are biologic drugs that work by blocking the IL-6 receptor, thereby reducing inflammation and immune response in conditions like rheumatoid arthritis. For instance, in February 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, obtained approval from the US Food and Drug Administration (FDA) for Kevzara. This approval designated Kevzara as the first and only biologic treatment for patients with polymyalgia rheumatica (PMR) who do not adequately respond to corticosteroids. Kevzara is a fully human monoclonal antibody designed to block the IL-6 receptor, which helps mitigate inflammation linked to PMR, a condition primarily affecting older adults and causing muscle pain and stiffness. Unlike traditional steroids, which carry risks such as osteoporosis and diabetes with prolonged administration, Kevzara offers a more targeted, steroid-sparing approach, supporting enhanced patient outcomes and improved long-term safety.

Which Firms Are Influencing Competition In The Anti-Inflammatory Biologics Market?

Major companies operating in the anti-inflammatory biologics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, AbbVie Inc, Sanofi S.A, Bristol-Myers Squibb, Novartis AG, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc, UCB S.A

Get The Full Anti-Inflammatory Biologics Market Report:

https://www.thebusinessresearchcompany.com/report/anti-inflammatory-biologics-global-market-report

Where Is The Anti-Inflammatory Biologics Market Primarily Concentrated By Region?

North America was the largest region in the anti-inflammatory biologics market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-inflammatory biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Anti-Inflammatory Biologics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/anti-inflammatory-biologics-global-market-report

Browse Through More Reports Similar to the Global Anti-Inflammatory Biologics Market 2026, By The Business Research Company

Anti Inflammatory Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-inflammatory-therapeutics-global-market-report

Non Steroidal Anti Inflammatory Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-steroidal-anti-inflammatory-drugs-global-market-report

Rare Inflammatory Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795